Diammonium glycyrrhizinate

Phase 3Small molecule

NNanfang Hospital, Southern Medical University

Diammonium glycyrrhizinate is one of 67 small molecule programs targeting Chronic Hepatitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic HepatitisActive, not recruiting

Hepatocellular CarcinomaActive, not recruiting

Chronic HepatitisPhase 3

Active, not recruiting

Hepatocellular CarcinomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

797 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

Diammonium glycyrrhizinate

NNanfang Hospital, Southern Medical University

Phase 3

1 2

Ibrance

Pfizer

Preclinical

1 3

Viread

Gilead

Preclinical

1 4

Sovaldi

Gilead

Preclinical

1 5

Hepsera

Coreg

2 7

Apatinib

LLaNova Medicines Zhejiang Co., Ltd.

Preclinical

16 8

Doptelet

AAkarx

Preclinical

1 9

Miraclid

TTechpool Bio-Pharma Co., Ltd.

Preclinical

1 10

Vermox

WWim Janssens

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Hepatitis2 trials

Magnesium Isoglycyrrhizinate Followed by Diammonium Glycyrrhizinate and Combined With Entecavir in Chronic Hepatitis B

Unknown status·CCttq·Phase 4·NCT03349008·480 enrolled

Efficacy of Medical Ozone Therapy in Patients With Chronic Hepatitis B

Unknown status·NNanfang Hospital, Southern Medical University·Phase 3·NCT01342185·189 enrolled

Hepatocellular Carcinoma1 trial

Ulinastatin Preventing Postoperative Hepatic Failure in Hepatocellular Carcinoma (HCC)

Completed·—·N/A·NCT01643447·200 enrolled

Randomized1 trial

A Multicenter Randomized Open-label Study of Diammonium Glycyrrhizinate Enteric-coated Capsule Plus DXM Versus DXM in Treatment of ITP

Active, not recruiting·SShandong University·Phase 2·NCT05023915·106 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Diammonium glycyrrhizinate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Diammonium glycyrrhizinate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Diammonium glycyrrhizinate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nanfang Hospital, Southern Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNanfang Hospital, Southern Medical University

Diammonium glycyrrhizinate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Hepatitis2 trials

Hepatocellular Carcinoma1 trial

Randomized1 trial

References

Drug Info

Quick Facts

Related News